East India Pharmaceutical Works
Ninety-year-old Kolkata generics maker with ₹272 Cr of revenue, thin margins and a ₹39 dealer quote against a ₹10 face value.
Market cap
₹26.01 Cr
0.67 Cr shares
P/E ratio
5.91
Sector average 28
Book value
₹90.96
P/B 0.43
1-year return
+0.00%
52w ₹39 – ₹39
Currently 0% of the way through its 52-week range.
Indicative price history
1Y change
+0.00% ₹39 → ₹39
52-week band in this window: ₹39.00 – ₹39.00. Weekly indicative marks, not exchange-traded prices.
Key highlights
- Incorporated 1936; one of Kolkata's oldest pharmaceutical manufacturers.
- Revenue ₹272 Cr in FY25 (+9%), operating margin 4–5% per ICRA.
- Dealer quote ₹39 on a ₹10 face value — market value under ₹30 Cr.
About East India Pharma
East India Pharmaceutical Works Ltd (EIPWL) is one of the oldest surviving Indian pharmaceutical companies, incorporated in Kolkata in April 1936. It manufactures and markets generic formulations — tablets, capsules, liquids and injectables — across anti-infective, gastro-intestinal, analgesic and nutritional therapies, sold through a domestic distribution network and institutional tenders.
ICRA's rating rationale records a top line of ₹272 Cr in FY25, up 9% from ₹249 Cr in FY24 and ₹233.7 Cr in FY23, with operating margins compressed to 4–5% against 6–7% earlier because of input-cost inflation and pricing pressure in generics. The company is described as a moderate-sized player with limited economies of scale.
The equity has a ₹10 face value and paid-up capital of ₹6.67 Cr, giving roughly 66.7 lakh shares. Dealer quotes on wwipl.com stand at ₹39, down from about ₹100 quoted by some dealers in late 2025, so the whole company is valued at under ₹30 Cr on a ₹272 Cr revenue base.
Figures preliminary; verify from MCA filings. Revenue and margin figures are taken from ICRA rationales; balance-sheet and cash-flow lines are estimates pending the FY25 annual report.
Where the revenue comes from
- Domestic branded and generic formulations80%
Tablets, capsules, liquids and injectables sold through distributors
- Institutional and tender supplies15%
Government and hospital tenders
- Other5%
Contract manufacturing and miscellaneous
Products & services
Anti-infectives and analgesics
Generic tablets and capsules for the domestic market
Liquids and injectables
Oral liquids and small-volume injectables including institutional supplies
What works
- • Nine decades of operating history and an established generic-formulation brand in eastern India.
- • Steady revenue growth: ₹233.7 Cr (FY23) → ₹249 Cr (FY24) → ₹272 Cr (FY25), backed by stable demand for its key molecules.
- • Externally rated by ICRA; the November 2025 review expects an adequate financial profile with improved accrual generation.
What to watch
- • Operating margins of only 4–5%; small changes in input costs swing profit sharply (profit fell 63% in FY23).
- • Intense competition in Indian generics limits pricing power and economies of scale for a ₹272 Cr player.
- • Dealer quotes have dropped from ~₹100 to ₹39 within a year, and liquidity is thin — exits can take weeks.
- • Balance-sheet and profit figures on this page are preliminary estimates pending the audited FY25 filing.
Compare with peers
| Company | Price | Market cap | P/E | P/B | Rev CAGR |
|---|---|---|---|---|---|
| East India PharmaThis page | ₹39.00 | ₹26.01 Cr | 5.91 | 0.43 | +7.88% |
| Martin & Harris | ₹959.00 | ₹479.5 Cr | 11.99 | 1.88 | +9.92% |
| Pharmed | ₹820.00 | ₹353.11 Cr | 4.37 | 1.19 | +13.55% |
Latest reported year: FY25 ending 31 Mar 2025.